Naftifine: A Topical Allylamine for Superficial Dermatophytosis.
| Autor: | Trailokya AA; Head Medical Affairs; Corresponding Author., Shirsat AB; Manager Medical Services, Department of Indoco Remedies, Mumbai, Maharashtra., Madhu R; Associate Professor, Department of Dermatology, Venereology & Leprosy, Madras Medical College, Chennai, Tamil Nadu., Shah B; Professor and Head, Department of Dermatology, B J Medical College, Ahmedabad, Gujarat, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Journal of the Association of Physicians of India [J Assoc Physicians India] 2023 May; Vol. 71 (5), pp. 11-12. |
| DOI: | 10.5005/japi-11001-0241 |
| Abstrakt: | Dermatophytosis is a very common public health problem with high prevalence. Dermatophytes are a highly specialized set of filamentous fungi, which are adapted to keratinized tissues of humans and animals. Dermatophytosis is the most common fungal infection worldwide, affecting approximately 20-25% of the world's population. The etiological agents of dermatophytosis, called dermatophytes, change with geography and socioeconomic status. Trichophyton rubrum (T. rubrum) is the prime species for skin and nail infections followed by T. mentagrophytes/ T. interdigital complex. There is a shift from T. rubrum to T. mentagrophytes in India for superficial fungal infections. In order to deal with fungal infections, treatment strategies involve the use of systemic antifungals and/or topical antifungal agents. Naftifine is a synthetic allylamine antifungal first reported in 1974 and in 1985 became the first commercially available allylamine. The highly lipophilic nature of allylamine allows efficient penetration and reasonably high concentrations in the stratum corneum (SC) and hair follicles. Naftifine is fungicidal as well as fungistatic. The higher efficacy rates of allylamines over imidazoles for the treatment of fungal infections, even for months after cessation of treatment, is thought to be due to their fungicidal effect, as well as to potentially greater keratin binding and slower release from the SC. The effectiveness of naftifine is also demonstrated against various bacteria belonging to both gram-negative and gram-positive classes. The antiinflammatory property of naftifine has been reported in various preclinical studies where it has been shown to target the prostaglandin pathway. Naftifine 1 and 2% gel and cream is approved by The United States Food and Drug Administration (USFDA), recently naftifine has been approved in India by the Indian regulatory authority Drug Controller General of India (DCGI) for the treatment of dermatophytosis. Naftifine 2% also appears to be a promising treatment, requiring fewer applications than the 1% formulation. Naftifine appears to be effective in a single dose and has a shorter treatment duration than azoles. Naftifine demonstrated its efficacy and safety in various clinical studies of tinea infections. Naftifine offers a very useful and promising option for treating dermatophytosis. (© Journal of the Association of Physicians of India 2011.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|